Alexander J. Denner, Ph.D., Chairman
Alexander J. Denner has served as a director since May 2009 and chairman of Enzon’s Board of Directors since July 2009. Dr. Denner serves as Managing Director of entities affiliated with Carl C. Icahn, including Icahn Partners LP, Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP and Icahn Partners Master Fund III LP. Icahn Partners LP, Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP and Icahn Partners Master Fund III, all of which are private investment funds. Dr. Denner has served in this position since August 2006. From April 2005 to May 2006, Dr. Denner served as a portfolio manager specializing in healthcare investments for Viking Global Investors. Previously Dr. Denner served in a variety of roles at Morgan Stanley, beginning in 1996, including as portfolio manager of healthcare and biotechnology mutual funds. Dr. Denner was chairman of the Executive Committee of ImClone Systems Incorporated, a publicly traded biopharmaceutical company, and served as a director from 2006 until ImClone was purchased in 2008. He served as a director of Adventrx Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2006 to 2009. In addition, Dr. Denner has served as a director of Biogen Idec Inc., a publicly traded biopharmaceutical company, since 2009 and Amylin Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since 2009. Dr. Denner received his S.B. degree from the Massachusetts Institute of Technology and his M.S., M.Phil. and Ph.D. degrees from Yale University.
Richard C. Mulligan, Ph.D., Vice-Chairman
Richard C. Mulligan has served as a director since May 2009 and vice-chairman of Enzon’s Board of Directors since March 2011. Dr. Mulligan has been the Mallinckrodt Professor of Genetics at Harvard Medical School and Director of the Harvard Gene Therapy Initiative since 1996. Professor Mulligan received his B.S. degree from the Massachusetts Institute of Technology, and his Ph.D. from the Department of Biochemistry at Stanford University School of Medicine. After receiving postdoctoral training at the Center for Cancer Research at MIT, Dr. Mulligan joined the MIT faculty and subsequently was appointed professor of molecular biology and member of the Whitehead Institute for Biomedical Research before moving to Children’s Hospital and Harvard in 1996. His honors include the MacArthur Foundation Prize, the Rhodes Memorial Award of the American Association for Cancer Research, the ASMB-Amgen Award, and the Nagai Foundation International Prize. Professor Mulligan has been associated with a number of biotechnology companies, including DuPont (as consultant), Genetics Institute (as consultant), AMGEN (as consultant), Somatix Therapy Corporation (as founder, member of the Scientific Advisory Board and Board of Directors, and chief scientific officer), Cell Genesys, Inc. (as member of the Scientific Advisory Board), ImClone Systems Incorporated, a publicly traded biopharmaceutical company (as member of Scientific Advisory Board, Board of Directors and Executive Committee from 2006 until it was purchased in 2008), Cellectis SA, a publicly traded genome engineering company (as member of Board of Directors since 2007), Biogen Idec Inc., a publicly traded biotechnology company (as member of the Board of Directors since 2009) and Kadmon Pharmaceuticals (as vice-chairman of the Board of Directors and executive team since November 2010). He has also served on the National Institutes of Health’s Recombinant DNA Advisory Committee and on the U.S. Food and Drug Administration Biological Response Modifiers Advisory Committee.
Thomas F. Deuel, M.D.
Thomas F. Deuel has served as a director of Enzon since April 2010. Dr. Deuel is currently a professor of molecular and experimental medicine and cell biology, director of the Division of Molecular Oncology, Department of Molecular and Experimental Medicine, and director of the Vascular Biology Affinity Group at The Scripps Research Institute and has served in such positions since February 2002. In addition, since 1998, Dr. Deuel has served as a professor of medicine at Harvard Medical School, where he is currently a professor emeritus. From 1996 to 2002, Dr. Deuel served as a director in the Division of Growth Regulation at Beth Israel Hospital, Boston, Massachusetts and, prior to that, was a professor of medicine and biochemistry and the head of Oncology Services at the Washington University School of Medicine, St. Louis, Missouri. Dr. Deuel is a member of the Institute of Medicine at the National Academy of Sciences. Dr. Deuel is also president of the Edward R. Mallinckrodt Foundation, St. Louis, Missouri. He has served on various editorial boards, including the Journal of Clinical Investigation and Blood , and currently is on the editorial board of Current Opinion in Hematology and section editor for vascular biology. Dr. Deuel has served and continues to serve on numerous scientific advisory boards for various companies, including the Scientific Advisory Board of ImClone Systems Incorporated, a publicly traded biopharmaceutical company, from 1988 to 2001. From July 2007 to November 2008, Dr. Deuel served on ImClone’s board of directors. Dr. Deuel has earned many professional honors and awards and holds an M.D. from Columbia University.
George W. Hebard III, M.B.A.
George W. Hebard III was appointed as a director on February 27, 2012. He brings to the Board 15 years of experience working in finance and investment management, including a strong record as a financially sophisticated investor and a broad understanding of the operational, financial and strategic issues facing public and private companies. Since September 2011, Mr. Hebard has been a managing director at Icahn Capital LP. Prior to joining Mr. Icahn, Mr. Hebard served as a Managing Director at Blue Harbour Group from 2005 to 2011 and at Ranger Partners from 2002 to 2003. Previously, Mr. Hebard was an associate at Icahn Associates Corp., from 1998 to 2002. Mr. Hebard has an MBA from INSEAD and an A.B. in Economics from Princeton University.
Robert LeBuhn, M.B.A.
Robert LeBuhn has served as a director of Enzon since August 1994. A private investor, he has served on a number of corporate and non-profit boards. Mr. LeBuhn has been a trustee of the Geraldine R. Dodge Foundation since 1980 and he also serves on the Board of the New Jersey Performing Arts Center. He is an investment advisor to the Sidney E. Frank Foundation and the founding trustee of the Board of All Kinds of Minds, a non-profit institute for the understanding of differences in learning in Chapel Hill, North Carolina. Mr. LeBuhn is a director of Fiberforge, a developer of lightweight advanced composite parts. Mr. LeBuhn was chairman (1992-1994) and president (1984-1992) of the U.S. subsidiary of Investor AB of Stockholm, Sweden, part of the Wallenberg Group of Swedish companies, which notably includes ABB, AstraZeneca, Atlas-Copco, Scania, Electrolux and L. M. Ericsson. Mr. LeBuhn began his investment career at Cyrus J. Lawrence & Sons, in New York in 1957 and served with the Rothschild Inc. group (formerly New Court Securities Inc.) from 1981-1984. He also was an investment advisor to the Sid W. Richardson/Perry R. Bass interests of Fort Worth from 1962-1972. Mr. LeBuhn also served on the Board of US Airways, Inc. and its predecessor airlines for more than 37 years. He holds an M.B.A. from the Wharton School of the University of Pennsylvania.
Robert C. Salisbury, M.B.A.
Robert C. Salisbury has served as a director of Enzon since May 2005. In 1998, Mr. Salisbury retired from Pharmacia & Upjohn, Inc., where he had most recently served as Executive Vice President and Chief Financial Officer. Previously, Mr. Salisbury served as Executive Vice President, Finance and Chief Financial Officer at The Upjohn Company. Mr. Salisbury first joined The Upjohn Company in 1974 and over a career of more than 20 years, he served in various management posts in finance and strategic planning. Mr. Salisbury also serves as a director of Asterand plc, a publicly traded supplier of human tissue and human tissue-based research services. From 1998 to 2007, Mr. Salisbury was a director of Viragen, Inc., a publicly traded biopharmaceutical company.
Richard A. Young, Ph.D.
Richard A. Young has served as a director of Enzon since April 2010. Dr. Young is a member of the Whitehead Institute and a professor of biology at the Massachusetts Institute of Technology. Dr. Young has been a member of the Whitehead Institute since 1984. In 2006, Scientific American recognized Dr. Young as one of the top 50 leaders in science, technology and business. His other awards include a Burroughs Wellcome Scholarship, the Chiron Corporation Biotechnology Research Award and Yale’s Wilbur Cross Medal. Dr. Young has served as an advisor to Science magazine, the National Institutes of Health and the World Health Organization and received his Ph.D. from Yale University in 1975.